It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
With the rapid advancement of sequencing technologies, next generation sequencing (NGS) analysis has been widely applied in cancer genomics research. More recently, NGS has been adopted in clinical oncology to advance personalized medicine. Clinical applications of precision oncology require accurate tests that can distinguish tumor-specific mutations from artifacts introduced during NGS processes or data analysis. Therefore, there is an urgent need to develop best practices in cancer mutation detection using NGS and the need for standard reference data sets for systematically measuring accuracy and reproducibility across platforms and methods. Within the SEQC2 consortium context, we established paired tumor-normal reference samples and generated whole-genome (WGS) and whole-exome sequencing (WES) data using sixteen library protocols, seven sequencing platforms at six different centers. We systematically interrogated somatic mutations in the reference samples to identify factors affecting detection reproducibility and accuracy in cancer genomes. These large cross-platform/site WGS and WES datasets using well-characterized reference samples will represent a powerful resource for benchmarking NGS technologies, bioinformatics pipelines, and for the cancer genomics studies.
Measurement(s) | Somatic Mutation Analysis |
Technology Type(s) | whole genome sequencing • Whole Exome Sequencing |
Factor Type(s) | sequencing platform • sample prepration • library preparation • bioinformatics method |
Sample Characteristic - Organism | Homo sapiens |
Machine-accessible metadata file describing the reported data:
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Frederick National Laboratory for Cancer Research, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
2 Bioinformatics Research & Early Development, Roche Sequencing Solutions Inc., Belmont, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
3 Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
4 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
5 Loma Linda University, Center for Genomics, School of Medicine, Loma Linda, USA (GRID:grid.43582.38) (ISNI:0000 0000 9852 649X)
6 Core Applications Group, Product Development, Illumina Inc, Foster City, USA (GRID:grid.185669.5) (ISNI:0000 0004 0507 3954)
7 National Cancer Institute, National Institutes of Health, Computational Genomics and Bioinformatics Branch, Center for Biomedical Informatics and Information Technology, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
8 AbbVie Genomics Research Center, North Chicago, USA (GRID:grid.48336.3a)
9 Fudan University, State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
10 Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
11 Companion Diagnostics Development, Oncology Biomarker Development, Genentech, South San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
12 Palacky University, IMTM, Faculty of Medicine and Dentistry, Olomouc, Czech Republic (GRID:grid.10979.36) (ISNI:0000 0001 1245 3953); Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.10979.36)
13 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.10979.36); Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741)
14 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.418321.d); Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741)
15 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.418321.d); Perron Institute for Neurological and Translational Science, Nedlands, Australia (GRID:grid.482226.8) (ISNI:0000 0004 0437 5686); Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics, Murdoch, Australia (GRID:grid.1025.6) (ISNI:0000 0004 0436 6763)
16 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.1025.6); University of Tartu, Estonian Genome Centre, Institute of Genomics, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
17 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.10939.32); University of Helsinki, Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
18 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.7737.4); Uppsala University, Department of Medical Sciences, Molecular Precision Medicine and Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
19 Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.8993.b); Uppsala University, Department of Medical Sciences, Molecular Precision Medicine and Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
20 Weill Cornell Medicine, Department of Physiology and Biophysics, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
21 National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, USA (GRID:grid.419234.9) (ISNI:0000 0004 0604 5429)
22 National Center for Toxicological Research, U.S. Food and Drug Administration, FDA, Jefferson, USA (GRID:grid.483504.e) (ISNI:0000 0001 2158 7187)
23 The Center for Drug Evaluation and Research, U.S. Food and Drug Administration, FDA, Silver Spring, USA (GRID:grid.483500.a) (ISNI:0000 0001 2154 2448)